B+
Bull case
25%
Probability
Target price
$110.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
ZBH
Zimmer BiometCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Raised 2026 guidance, 4.0% Q2 organic constant-currency growth, and a robotics pipeline support a measured improvement case if commercial restructuring sustains execution. Company Q2 release Company leadership update
Posture
Mixed
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-24.
What can break
Adjusted Q2 EPS was unchanged year over year despite higher sales; guidance execution and margin conversion remain important. [#SEC-8K-2026-08-05]
Momentum
43
Value
64
Sentiment
45
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $97.00 · Bull $110.00 · Bear $73.00Analysis 2026-10-10; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-10 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $105.75
Why
Momentum43 · Δ7d -0.8
Value64 · Δ7d +0.0
Sentiment45 · Δ7d -2.8
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-24.
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Adjusted Q2 EPS was unchanged year over year despite higher sales; guidance execution and margin conversion remain important. [#SEC-8K-2026-08-05]
- • Americas leadership restructuring could disrupt sales execution before productivity benefits appear. [#8-K-2026-09-08]
- • Flat Q2 adjusted EPS and just 0.1% organic constant-currency knee growth leave the core franchise vulnerable to execution disappointment; a leadership transition adds uncertainty.
Catalyst clock
2026-12-31
Test of raised 2026 guidance
Lead driver: Value · See fundamentals
Momentum
43
8% active weight
Current posture
7d trendImproving
Δ7d
-0.8
Δ21d
+0.5
Value
64
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-1.0
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.8
Δ21d
-21.0
Why this grade
Composite grade C. Momentum 42.6 / Value 64.5 / Sentiment 45.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-10. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$97.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$73.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$18.8B
Beta
0.62
Shares Out
190.74M
P/E (TTM)
22.9
P/S (TTM)
2.29
P/FCF (TTM)
19.53
Rev YoY
+4.8%
EPS YoY
+33.5%
Gross Margin
+61.4%
Op Margin
+16.3%
Net Debt
$7.16B
Current Ratio
1.69
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data